Back to dashboard
CommercialReimbursementMedium impact

Reimbursement Policies

EmblemHealth·Neurology, Family Medicine, Internal Medicine +6 more·Provider News
Effective date
Not stated
We identified it
Jun 20, 2026
Days to comply
—

Summary

EmblemHealth and ConnectiCare have added a new Lab Benefit Management policy for biomarker testing in multiple sclerosis and updated over 30 existing lab testing policies. These changes affect reimbursement rules for various diagnostic tests including sexually transmitted infections, diabetes, cancer screenings, and other common lab work.

Action Required

Action needed
Review the revision histories of all updated Lab Benefit Management policies on the EmblemHealth provider portal to identify specific effective dates and changes. Update billing procedures for affected lab tests including MS biomarkers, STI testing, diabetes testing, cancer screenings, and other diagnostic lab work according to the new policy requirements.

Related policy hubs